Immix Biopharma (IMMX) Institutional Ownership $1.66 +0.09 (+5.73%) Closing price 04/17/2025 03:57 PM EasternExtended Trading$1.67 +0.01 (+0.60%) As of 04/17/2025 04:05 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Ownership Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Institutional Ownership Changes (13F Filings) for Immix Biopharma (NASDAQ:IMMX)CurrentInstitutional OwnershipPercentage11.26%Number ofInstitutional Buyers(last 12 months)7TotalInstitutional Inflows(last 12 months)$335.55KNumber ofInstitutional Sellers(last 12 months)4TotalInstitutional Outflows(last 12 months)$627.43K Get IMMX Insider Trade Alerts Want to know when executives and insiders are buying or selling Immix Biopharma stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address Skip Chart & View Institutional Buying and Selling Data IMMX Institutional Buying and Selling by Quarter Immix Biopharma Major Shareholders & Ownership History Export to ExcelReporting DateMajor Shareholder NameShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails2/14/2025Jane Street Group LLC17,523$39K0.0%N/A0.064% 2/6/2025SBI Securities Co. Ltd.17,500$38K0.0%N/A0.064% 1/13/2025 FNY Investment Advisers LLC28,750$63K0.0%N/A0.105% 11/16/2024Geode Capital Management LLC150,082$224K0.0%+5.6%0.546% 10/22/2024Private Advisor Group LLC34,325$51K0.0%-47.3%0.130% 8/16/2024Invst LLC27,000$57K0.0%N/A0.102% 8/12/2024XTX Topco Ltd17,663$35K0.0%-66.2%0.067% 8/9/2024Renaissance Technologies LLC154,685$306K0.0%-41.7%0.586% 8/7/2024AIGH Capital Management LLC1,406,680$2.79M0.9%-9.5%5.326% 5/10/2024Tocqueville Asset Management L.P.37,800$116K0.0%+89.0%0.143% Get the Latest News and Ratings for IMMX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Immix Biopharma and its competitors with MarketBeat's FREE daily newsletter. 4/26/2024 Tritonpoint Wealth LLC24,526$75K0.0%N/A0.093% 2/7/2024Jump Financial LLC18,500$128K0.0%N/A0.093% 2/6/2024Private Advisor Group LLC99,775$690K0.0%N/A0.502% 2/1/2024 OLD National Bancorp IN10,000$69K0.0%N/A0.050% 1/30/2024Imprint Wealth LLC34,483$239K0.2%+49.4%0.174% 11/9/2023Tocqueville Asset Management L.P.12,000$41K0.0%N/A0.061% 10/23/2023Commonwealth Equity Services LLC28,855$99K0.0%+26.4%0.147% 7/28/2023Koshinski Asset Management Inc.51,001$137K0.0%N/A0.339% 7/25/2023 UMB Bank n.a.72,639$195K0.0%-26.8%0.483% 4/11/2023 UMB Bank n.a.99,300$181K0.0%N/A0.714% 2/10/2023Murchinson Ltd.67,200$154K0.0%N/A0.482% 2/7/2023Lynwood Capital Management Inc.25,000$58K0.1%N/A0.179% 2/1/2023Bank of Montreal Can15,000$36K0.0%N/A0.108% 5/11/2022InterOcean Capital Group LLC15,900$38K0.0%N/A0.115% 2/14/2022Altium Capital Management LP122,388$436K0.1%N/A1.616% 2/14/2022Murchinson Ltd.695,600$2.48M0.2%N/A9.183% 2/9/2022Context Capital Management LLC11,532$41K0.0%N/A0.152% 2/2/2022PVG Asset Management Corp20,000$71K0.3%N/A0.264% 2/1/2022Eidelman Virant Capital29,856$103K0.0%N/A0.394% (Data available from 1/1/2016 forward) IMMX Institutional Ownership - Frequently Asked Questions Who are the largest shareholders of IMMX shares? During the previous two years, 17 institutional investors and hedge funds held shares of Immix Biopharma. The most heavily invested institutionals were AIGH Capital Management LLC ($2.79M), Renaissance Technologies LLC ($306K), Imprint Wealth LLC ($239K), Geode Capital Management LLC ($224K), UMB Bank n.a. ($195K), Koshinski Asset Management Inc. ($137K), and Jump Financial LLC ($128K).Learn more on IMMX's institutional investors. What percentage of Immix Biopharma stock is owned by institutional investors? 11.26% of Immix Biopharma stock is owned by institutional investors. Learn more on IMMX's institutional investor holdings. Which institutional investors have been buying Immix Biopharma stock? Of the 13 institutional investors that purchased Immix Biopharma stock in the last 24 months, the following investors and hedge funds have bought the highest volume of shares: Private Advisor Group LLC ($99.78K), Koshinski Asset Management Inc. ($51.00K), Tocqueville Asset Management L.P. ($29.80K), FNY Investment Advisers LLC ($28.75K), Invst LLC ($27K), Tritonpoint Wealth LLC ($24.53K), and Jump Financial LLC ($18.50K). How much institutional buying is happening at Immix Biopharma? Institutional investors have bought a total of 349,759 shares in the last 24 months. This purchase volume represents approximately $1.50M in transactions. Which Immix Biopharma major shareholders have been selling company stock? The following institutional investors have sold Immix Biopharma stock in the last 24 months: AIGH Capital Management LLC ($148.32K), Renaissance Technologies LLC ($110.82K), XTX Topco Ltd ($34.53K), Private Advisor Group LLC ($30.85K), and UMB Bank n.a. ($26.66K). How much institutional selling is happening at Immix Biopharma? Institutional investors have sold a total of 351,180 shares in the last 24 months. This volume of shares sold represents approximately $699.15K in transactions. Related Companies Eledon Pharmaceuticals Institutional Ownership Cardiff Oncology Institutional Ownership MediWound Institutional Ownership Tevogen Bio Institutional Ownership Voyager Therapeutics Institutional Ownership Genfit Institutional Ownership Inventiva Institutional Ownership Prime Medicine Institutional Ownership INmune Bio Institutional Ownership Inhibrx Institutional Ownership This page (NASDAQ:IMMX) was last updated on 4/20/2025 by MarketBeat.com Staff From Our PartnersTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredTrump’s Top Secret $9 Trillion AI SuperweaponJeff Brown spotted Nvidia at $1. Now he’s revealing a new AI superweapon — and the Musk-connected stocks that ...Brownstone Research | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredMusk’s AI Masterplan – Our #1 AI Stock to Buy NowDid Elon Musk just set the stage for the next AI stock explosion? One 30-year Wall Street veteran thinks so...Behind the Markets | SponsoredClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredAltucher: Turn $900 into $108,000 in just 12 months?We are entering the final Trump Bump of our lives. But the biggest returns will not be in the stock market.Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immix Biopharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immix Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
